Phase I Human Safety Studies of FGI-101-1A6 to Combat HINI Influenza Virus

Abstract

FGI-101-1A6 is a broad spectrum anti-TSG101 monoclonal antibody demonstrating broad in vitro anti-viral activity against several strains of Influenza and HIV. Under this contract, Functional Genetics will complete Phase Ia Human Safety Studies and an efficacy study against HIV in primates. This report describes the status of the program to date as well as outline the activities to be performed in the next period.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jun 20, 2013
Accession Number
ADA607997

Entities

People

  • Leyla Diaz

Tags

Communities of Interest

  • Biomedical

DTIC Thesaurus Topics

  • Antibodies
  • Artificial Organs
  • Blood Chemistry
  • Chemistry
  • Clinical Trials
  • Contracts
  • Experimental Design
  • Health Services
  • Hiv Infections
  • Infection
  • Medical Personnel
  • Monitoring
  • Physical Examination (Medicine)
  • Test And Evaluation
  • Viruses
  • Vital Signs
  • Wound Infections

Fields of Study

  • Biology

Readers

  • Business Analytics
  • Immunology

Technology Areas

  • Biotechnology